- Home
- RNA
as 08-15-2025 12:41pm EST
Avidity Biosciences Inc is a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates, or AOCs. Company's pipeline currently has three programs in potentially registrational clinical trials: DM1, FSHD, and DMD. The segments includes following: Del-zota for DMD44, Del-desiran for DM1, Del-brax for FSHD.
| Founded: | 2012 | Country: | United States |
| Employees: | N/A | City: | SAN DIEGO |
| Market Cap: | 4.0B | IPO Year: | 2020 |
| Target Price: | $68.40 | AVG Volume (30 days): | 3.7M |
| Analyst Decision: | Strong Buy | Number of Analysts: | 15 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -3.57 | EPS Growth: | N/A |
| 52 Week Low/High: | $21.51 - $56.00 | Next Earning Date: | 08-07-2025 |
| Revenue: | $10,729,000 | Revenue Growth: | 1.23% |
| Revenue Growth (this year): | -36.87% | Revenue Growth (next year): | 196.18% |
Stock Insider Trading Activity of Avidity Biosciences Inc. (RNA)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Gallagher Kathleen P. | RNA | Chief Program Officer | Jun 17 '25 | Sell | $30.24 | 911 | $27,548.64 | 50,392 | |
| Gallagher Kathleen P. | RNA | Chief Program Officer | Jun 2 '25 | Sell | $32.48 | 5,875 | $190,832.93 | 50,392 |
Latest Avidity Biosciences Inc. News
RNA Breaking Stock News: Dive into RNA Ticker-Specific Updates for Smart Investing
MT Newswires
2 months ago
Bernstein Initiates Avidity Biosciences at Outperform With $50 Price Target
MT Newswires
2 months ago
Wolfe Research Initiates Coverage on Avidity Biosciences With Outperform Rating, $55 Price Target
Insider Monkey
2 months ago
Avidity Biosciences, Inc. (RNA) Initiated with a Strong Buy at Raymond James
Investing.com
2 months ago
Raymond James bullish on biotech firms on favorable valuation
PR Newswire
2 months ago
Avidity Biosciences to Present Topline Data from Phase 1/2 FORTITUDE™ Trial of Del-brax in People Living with Facioscapulohumeral Muscular Dystrophy at 32nd Annual FSHD Society International Research Congress
TipRanks
2 months ago
Avidity Biosciences price target raised to $75 from $65 at Chardan
Benzinga
2 months ago
Avidity Biosciences Touts Encouraging Functional Gains And Biomarker Reductions In Rare Muscular Weakness Disease Trial
PR Newswire
2 months ago
Avidity Biosciences Announces Positive Topline Phase 1/2 FORTITUDE™ Data Demonstrating Consistent Improvement Across Multiple Functional Measures Compared to Placebo in Del-Brax Treated FSHD Participants
Compare RNA vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "RNA Avidity Biosciences Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.